MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 1, 2008, Pages 32-39

  Eren, Bulent ^a,b   Sar, Mehmet ^c   Oz, Buge ^c   Oner Dincbas, Fazilet H ^c  

^a ULUDAG UNIVERSITY   (Turkey)

^b Council of Forensic Medicine of Turkey Bursa Morgue Department ^*  (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Immunohistochemistry; Metastasis; Pulmonary neoplasms

Indexed keywords

CD44V6 ANTIGEN; GELATINASE A; METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 41149106046     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002;29(1 Suppl 4):78-86.
2. Passlick B, Sienel W, Seen-Hibler R, Wockel W, Thetter O, Mutschler W, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000;6:3944-8.
3. Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S, et al. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in non-small cell lung carcinomas. Lung Cancer 2002;35:249-55
4. Albelda S. Biology of disease role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Inv 1993;68:4-17.
5. Wimmel A, Kogan E, Ramaswamy A, Schuermann M. Variant expression of CD44 in preneoplastic lesions of the lung. Cancer 2001;92:1231-36.
6. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994;54:4539-46.
7. Fasano M, Sabatini MT, Wieczorek R, Sidhu G, Goswami S, Jagirdar J. CD44 and its v6 spliced variant in lung tumors: a role in histogenesis? Cancer 1997;80:34-41.
8. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2- dependent invasion. J Biol Chem 2002;277:50828-33.
9. Cox G, Jones JL, Andi A, Waller DA, O'Byrne KJ. A biological staging model for operable non-small cell lung cancer. Thorax 2001;56:565-6.
10. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, et al. Differential expression of E-caherin and type IV collagenase genes predicts outcome in patient with stage I non-small cell lung carcinoma. Clin Cancer Res 2000;6:790-7.
11. Cox G, Jones LJ, O'ByRne JK. Matrix metalloproteinase 9 and epidermal growth factor signal pathway in operable non-small cell lung cancer .Clin Cancer Res 2000;6:2349-55.
12. Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001;95:1-4
13. Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma metalloproteinase 9 in non-small cell lung cancer patient. Clin Cancer Res 1999;5:49-53.
14. Delebecq TJ, Porte H, Zerimech F, Copin MC, Gouyer V, Dacquembronne E, et al. Overexpression level of stromalysin 3 is related to the lymph node involvement in non-small cell lung cancer. Clin Cancer Res 2000;6:1086-92.
15. Fujise N, Nanashim A, Taniguchi Y, Matsuo S, Hatano K, Matsumoto Y, et al. Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarsinomas by immunohistochemical study. Lung Cancer 2000;27:19-26.
16. Ylisirnio S, Hoyhtya M, Makitaro R, Paaakko P, Risteli J, Kinnula VL, et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001;7:1633-37.
17. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998;15:1108-10.
18. Wimmel A, Schilli M, Kaiser U, Havemann K, Ramaswamy A, Branscheid D, et al. Preferential histiotypic expression CD44-isoforms in human lung cancer. Lung Cancer 1997;16:151-72.
19. Takigawa N, Segawa Y, Mandai K, Takata I, Fujimoto N. Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features. Lung Cancer 1997;18:147-57.
20. Tran TA, Kallakury BV, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 1997;28:809-14.
21. Nguyen VN, Mirejovsky T, Melinova L, Mandys V. CD44 and ist v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma 2000;47:400-8.
22. Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases.Cancer 1999;86:1174-81.
23. Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 2001;438:121-8.
24. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002;86:1876-83.
25. Cox G, Jones JL, Walker RA, Steward WP, O'Byrne KJ.Angiogenesis and non-small cell lung cancer. Lung Cancer 2000;27:81-100.